Toya Bowles, PharmD, MS, BCPP

Long-Term Safety of Esketamine Nasal Spray Dosed in Accordance With US Prescribing Information in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study Up to 6.5 Years

This subgroup analysis of SUSTAIN-3 (NCT02782104), an open-label extension study of esketamine nasal spray (ESK), assessed the long-term safety of flexibly dosed ESK in combination with a...

Toya Bowles , PharmD, MS, BCPP;

10/26/2023

Long-Term Efficacy of Esketamine Nasal Spray Dosed in Accordance With US Prescribing Information in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study Up to 6.5 Years

This subgroup analysis of SUSTAIN-3 (NCT02782104), a phase 3, open-label extension study of esketamine nasal spray (ESK), assessed the long-term efficacy of flexibly dosed ESK in combinat...

Toya Bowles , PharmD, MS, BCPP;

10/26/2023